CG ONCOLOGY, INC. COMMON STOCK reports a Return on Equity (ROE) of -17.10%.

What is CGON's dividend yield?

CG ONCOLOGY, INC. COMMON STOCK offers a dividend yield of 0.00%.

What is CGON's Deepscope Quality Score?

Deepscope rates CGON's overall financial quality at 15 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy CGON?

Deepscope's AI Timing Score for CGON is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does CGON belong to?

CG ONCOLOGY, INC. COMMON STOCK is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.

CGON (NASDAQ) 株価分析 | CG ONCOLOGY, INC. COMMON STOCK

Stock Check Daily update data at 9:30 AM
(Price: 2026-06-08 | FS: 2026-03-31)

CGON

CG ONCOLOGY, INC. COMMON STOCK

US:NASDAQ STOCK Healthcare >> Biotechnology News 89

USD 54.40

0.68 (1.27%) Day Change

Watchlist Portfolio Compare Chart

0.00

D/E

-17.1%

ROE

-16.5%

ROA

0.00%

Div Yield

CG ONCOLOGY, INC. COMMON STOCK
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 54.40 Price 0.68 (1.27%) Day Change	NEWS SCORE: 89

CGON, ファンダメンタルスコアはnot good ( ファンダメンタル = 15) そしてテクニカルスコアは ...(Sign In to See)...

Loading chart...

15 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROEが低い
ROAが低い
ROEの伸びが低い
平均ROEが低い
昨年度のROEが一昨年比で低い
ROAがROEに比べて低い
ROAの伸びが低い
Last-year ROA is lower than last-2-years ROA.
NPMが低い
NPMの伸びが低い
NPMの伸びが低い

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Lorem ipsum dolor sit amet

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...

Deepscope 分析

41%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	89
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	54.40
PBV / Sector	4.34 / 4.75
Earning Per Share	-2.14

PE / Sector	N/A / 17.65
PEG or PE/Growth / Sector	N/A / 0.52
Average 1M Daily Value	56.83 M
Average 1W Daily Value	48.68 M GREAT

Timing Factors

42%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

45%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

ポイントになる統計

52%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	-3,682.61 / 468.85
NPM Average (%) / Sector	-11,556.13 / -1,531.69
NPM Change Average (%) / Sector	-23.80 / 5,028.65
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-16.45 / 31.69
ROA Average (%) / Sector	-19.37 / -353.18
ROA Change Average (%) / Sector	1.18 / 5,214.65
ROE (%) / Sector	-17.10 / 10.58
ROE Average (%) / Sector	-21.02 / 27.64
ROE Change Average (%) / Sector	-0.83 / 2,048.88
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

配当

Dividend (%) / Sector	N/A / 0.05
Dividend Average (%) / Sector	N/A / 16.49
Dividend Change Average (%) / Sector	N/A / 3.97

登録情報

Analyze Date	2026-06-09 09:39:41
Symbol	CGON
Name	CG ONCOLOGY, INC. COMMON STOCK
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	88.20 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	4,738.24 / 9,000.42

ニュース

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 3000 Pegasus Park Drive, Dallas, TX, United States, 75247

Phone: 949 409 3700

Website: https://cgoncology.com

Employees: 142

Sector: Healthcare >> Biotechnology

Description: CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company's product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC. It also develops cretostimogene monotherapy for intermediate-risk NMIBC following TURBT, which is in phase 3 PIVOT-006 clinical trials to assess the safety and efficacy of adjuvant cretostimogene; and cretostimogene monotherapy for high-risk NMIBC in phase 2 CORE-008 clinical trials to assess the safety and clinical outcomes of cretostimogene in treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC. The company was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. CG Oncology, Inc. was founded in 2010 and is headquartered in Dallas, Texas.